Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 39

1.

Correction: First evaluation of the Next-Generation Sequencing platform for the detection of HIV-1 drug resistance mutations in Belgium.

Dessilly G, Goeminne L, Vandenbroucke AT, Dufrasne FE, Martin A, Kabamba-Mukadi B.

PLoS One. 2019 Jan 25;14(1):e0211587. doi: 10.1371/journal.pone.0211587. eCollection 2019.

2.

First evaluation of the Next-Generation Sequencing platform for the detection of HIV-1 drug resistance mutations in Belgium.

Dessilly G, Goeminne L, Vandenbroucke AT, Dufrasne FE, Martin A, Kabamba-Mukadi B.

PLoS One. 2018 Dec 31;13(12):e0209561. doi: 10.1371/journal.pone.0209561. eCollection 2018. Erratum in: PLoS One. 2019 Jan 25;14(1):e0211587.

3.

Short Communication: An Insertion of Seven Amino Acids in the Envelope Cytoplasmic Tail of HIV-2 Selected During Disease Progression Enhances Viral Replication.

Dufrasne FE, Lucchetti M, Dessilly G, Ruelle J, Martin A, Kabamba-Mukadi B.

AIDS Res Hum Retroviruses. 2019 Feb;35(2):185-190. doi: 10.1089/AID.2018.0129. Epub 2018 Oct 16.

PMID:
30229676
4.

I3-Ag85 effect on phthiodiolone dimycocerosate synthesis.

Rens C, Laval F, Wattiez R, Lefèvre P, Dufrasne F, Daffé M, Fontaine V.

Tuberculosis (Edinb). 2018 Jan;108:93-95. doi: 10.1016/j.tube.2017.10.007. Epub 2017 Oct 24.

PMID:
29523333
5.

Targeting Cytosolic Phospholipase A2α for Novel Anti-Inflammatory Agents.

Soubhye J, van Antwerpen P, Dufrasne F.

Curr Med Chem. 2018;25(21):2418-2447. doi: 10.2174/0929867325666180117103919. Review.

PMID:
29345571
6.

31ièmes Journées Franco-Belges de Pharmacochimie: Meeting Report.

Frédérick R, Pochet L, De Tullio P, Dufrasne F.

Pharmaceuticals (Basel). 2017 Dec 4;10(4). pii: E94. doi: 10.3390/ph10040094.

7.

Modulation of the NF-κB signaling pathway by the HIV-2 envelope glycoprotein and its incomplete BST-2 antagonism.

Dufrasne FE, Lucchetti M, Martin A, André E, Dessilly G, Kabamba B, Goubau P, Ruelle J.

Virology. 2018 Jan 1;513:11-16. doi: 10.1016/j.virol.2017.09.024. Epub 2017 Oct 11.

8.

Discovery of Novel Potent Reversible and Irreversible Myeloperoxidase Inhibitors Using Virtual Screening Procedure.

Soubhye J, Chikh Alard I, Aldib I, Prévost M, Gelbcke M, De Carvalho A, Furtmüller PG, Obinger C, Flemmig J, Tadrent S, Meyer F, Rousseau A, Nève J, Mathieu V, Zouaoui Boudjeltia K, Dufrasne F, Van Antwerpen P.

J Med Chem. 2017 Aug 10;60(15):6563-6586. doi: 10.1021/acs.jmedchem.7b00285. Epub 2017 Jul 19.

PMID:
28671460
9.

From Dynamic Combinatorial Chemistry to in Vivo Evaluation of Reversible and Irreversible Myeloperoxidase Inhibitors.

Soubhye J, Gelbcke M, Van Antwerpen P, Dufrasne F, Boufadi MY, Nève J, Furtmüller PG, Obinger C, Zouaoui Boudjeltia K, Meyer F.

ACS Med Chem Lett. 2016 Dec 2;8(2):206-210. doi: 10.1021/acsmedchemlett.6b00417. eCollection 2017 Feb 9.

10.

A survey of the mechanisms of action of anticancer transition metal complexes.

Marloye M, Berger G, Gelbcke M, Dufrasne F.

Future Med Chem. 2016 Dec;8(18):2263-2286. Epub 2016 Nov 22. Review.

PMID:
27874280
11.
12.

Novel bis-arylalkylamines as myeloperoxidase inhibitors: Design, synthesis, and structure-activity relationship study.

Aldib I, Gelbcke M, Soubhye J, Prévost M, Furtmüller PG, Obinger C, Elfving B, Alard IC, Roos G, Delporte C, Berger G, Dufour D, Zouaoui Boudjeltia K, Nève J, Dufrasne F, Van Antwerpen P.

Eur J Med Chem. 2016 Nov 10;123:746-762. doi: 10.1016/j.ejmech.2016.07.053. Epub 2016 Jul 25.

PMID:
27537923
13.

Characterization of chemical features of potent myeloperoxidase inhibitors.

Soubhye J, Meyer F, Furtmüller P, Obinger C, Dufrasne F, Antwerpen PV.

Future Med Chem. 2016 Jul;8(11):1163-77. doi: 10.4155/fmc-2016-0031. Epub 2016 Jul 12.

PMID:
27402298
14.

Myeloperoxidase as a Target for the Treatment of Inflammatory Syndromes: Mechanisms and Structure Activity Relationships of Inhibitors.

Soubhye J, Aldib I, Delporte C, Prévost M, Dufrasne F, Antwerpen PV.

Curr Med Chem. 2016;23(35):3975-4008. Review.

PMID:
27281130
15.

Resonant X-ray emission spectroscopy of platinum(II) anticancer complexes.

Sá J, Czapla-Masztafiak J, Lipiec E, Kayser Y, Fernandes DL, Szlachetko J, Dufrasne F, Berger G.

Analyst. 2016 Feb 21;141(4):1226-32. doi: 10.1039/c5an02490k.

PMID:
26805912
16.

Technologies to develop new metal medicines.

Dufrasne F.

Drug Discov Today Technol. 2015 Sep;16:31-2. doi: 10.1016/j.ddtec.2015.10.001. No abstract available.

PMID:
26547419
17.

The use of Resonant X-ray Emission Spectroscopy (RXES) for the electronic analysis of metal complexes and their interactions with biomolecules.

Sá J, Czapla-Masztafiak J, Lipiec E, Kayser Y, Kwiatek W, Wood B, Deacon GB, Berger G, Dufrasne F, Fernandes DL, Szlachetko J.

Drug Discov Today Technol. 2015 Sep;16:1-6. doi: 10.1016/j.ddtec.2015.07.001. Epub 2015 Sep 1. Review.

PMID:
26547415
18.

Type 2 17-β hydroxysteroid dehydrogenase as a novel target for the treatment of osteoporosis.

Soubhye J, Alard IC, van Antwerpen P, Dufrasne F.

Future Med Chem. 2015;7(11):1431-56. doi: 10.4155/fmc.15.74. Review.

PMID:
26230882
19.

Insights into the structure-activity relationships of chiral 1,2-diaminophenylalkane platinum(II) anticancer derivatives.

Berger G, Fusaro L, Luhmer M, Czapla-Masztafiak J, Lipiec E, Szlachetko J, Kayser Y, Fernandes DL, Sá J, Dufrasne F, Bombard S.

J Biol Inorg Chem. 2015 Jul;20(5):841-53. doi: 10.1007/s00775-015-1270-6. Epub 2015 May 16.

PMID:
25982100
20.

Synthesis and in vitro characterization of platinum(II) anticancer coordinates using FTIR spectroscopy and NCI COMPARE: A fast method for new compound discovery.

Berger G, Leclercqz H, Derenne A, Gelbcke M, Goormaghtigh E, Nève J, Mathieu V, Dufrasne F.

Bioorg Med Chem. 2014 Jul 1;22(13):3527-36. doi: 10.1016/j.bmc.2014.04.017. Epub 2014 Apr 19.

PMID:
24818960

Supplemental Content

Loading ...
Support Center